In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 15 days of free consultation

In these unprecedented times, the ESC is doing everything it can to support its community: FREE access to all ESC 365 content until 31 July: explore more than 125,000 educational resources.

From 1 August onwards, support our mission by becoming a member.

Free circulating miRNAs (miR1, miR-133a, miR-208a, miR-499) differentiate clinical types of coronary disease: acute myocardial infarction, unstable angina and stable coronary artery disease

Session Poster session 4

Speaker Dawid Miskowiec

Event : ESC Congress 2016

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Non-ST-Elevation Myocardial Infarction (NSTEMI)
  • Session type : Poster Session

Authors : D Miskowiec (Lodz,PL), P Lipiec (Lodz,PL), K Kupczynska (Lodz,PL), M Ojrzanowski (Lodz,PL), M Simiera (Lodz,PL), K Wierzbowska-Drabik (Lodz,PL), P Wejner-Mik (Lodz,PL), B Michalski (Lodz,PL), JD Kasprzak (Lodz,PL)

D. Miskowiec1 , P. Lipiec1 , K. Kupczynska1 , M. Ojrzanowski1 , M. Simiera1 , K. Wierzbowska-Drabik1 , P. Wejner-Mik1 , B. Michalski1 , J.D. Kasprzak1 , 1Medical University of Lodz, Chair and Departmentof Cardiology - Lodz - Poland ,

European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 780-781

Background: The microRNAs (miRs) are small non-coding RNA molecules regulating expression of multiple genes, which can be quantified using reverse transcription quantitative PCR methods. Some studies reported their utility in ST elevation myocardial infarction (STEMI) diagnostic process, whereas their diagnostic value in non-ST elevation acute coronary syndrome (NSTE-ACS) remains unclear.

Purpose: We sought to evaluate the expression of 5 free circulating miRs (miR-1, miR-21, miR-133a, miR-208a, miR-499) and their diagnostic value for distinguishing NSTE-ACS from stable coronary artery disease (SCAD).

Material and methods: Our study was daesigned as prospective, single-center observational study. The study group was composed of 72 patients (pts) with NSTE-ACS (mean age 66.1±11.6, 28% female) with symptoms onset <24 hours before the hospital admission and 34 pts with confirmed SCAD (mean age 65.3±10.5, 32% female) as controls. Blood was sampled twice in the NSTE-ACS group (at admission and 4 h after) and once in SCAD. Unstable angina (UA) vs non-STEMI diagnosis was based on the troponin 99th percentile rule, according to the current guidelines. Relative expression of miRs were calculated using the ΔΔCt method after normalization to the cel-miR-39 spiked-in control. The mean value of miRs' relative expression from two time samples in NSTE-ACS pts were used for further analysis.

Results: Free circulating miRs (except mir-21) were significantly elevated in pts with diagnosed NSTEMI: miR-1 levels were increased 6.5-fold (p<0.001), miR-133a 23.6-fold (p<0.001), miR-208a 4.0-fold (p=0.033) and miR-499 8.2-fold as compared to controls with SCAD. Moreover, miR-1 levels were increased 7.5-fold (p<0.001), miR-133a 5.8-fold (p=0.033) and miR-499 7.0-fold (p=0.003) when comparing NSTEMI to UA patients, and additionally two of them were able to discriminate between UA and SCAD patients: miR-133a (p=0.005) and miR-208a (p=0.035). Three of analyzed miRs were able to differentiate any NSTEMI individuals from other patients: miR-1 [area under the curve (AUC) 0.863, 95% CI 0.761–0.933, p<0.001], miR-133a (AUC 0.799, 95% CI 0.687–0.885, p<0.001) and miR-499 (AUC 0.766, 95% CI 0.651–0.858, p<0.001). MiR-1 elevation >12.2 fold yielded a sensitivity of 74.4% and specificity of 90.6%, miR-21 elevation >23.8 fold 74.4% and 84.4%, miR-499 elevation >4.7 fold 64.1% and 93.8% for distinguishing NSTEMI vs others.

Conclusions: The present study describes a unique signature of three circulating miRNAs as a robust biomarker to distinguish not only NSTEMI patients from other individuals (miR-1, miR-208a, miR-133a, miR-499), but also NSTEMI from UA patients (miR-1, miR-133a, miR-499) and UA from SCAD (miR-133a and miR-208a).

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are